Reply: Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data
Restricted accessLetterFirst published online September, 2020
Reply: Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data
DanneTGargSPetersAL, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42:1147-1154. doi:10.2337/dc18-2316
2.
BoJLiWChenZ, et al. D-lactate: a novel contributor to metabolic acidosis and high anion gap in diabetic ketoacidosis. Clin Chem. 2013;59:1406-1407. doi:10.1373/clinchem.2013.208777
3.
Couselo-SeijasMAgra-BermejoRMFernandezAL, et al. High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment. Atherosclerosis. 2020;292:60-69. doi:10.1016/j.atherosclerosis.2019.11.016
4.
RosenstockJFerranniniE. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638-1642. doi:10.2337/dc15-1380
